Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product
July 08 2019 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International Develops
Glucoraphanin + NanoStilbene Encapsulated product for
reduction of Prostate Specific Antigen (PSA)
OCEANSIDE, CA -- July
8, 2019 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today
the development of
a
broccoli sprout extract containing the precursor glucoraphanin in a
combined 200mg dose of NanoStilbene.
As previously
announced, the same
NanoStilbene
that
was
administered to twelve patients with advanced solid cancers for 3
weeks is the base
for this new product we
are calling "NanoPSA". Daily
treatment with 300mg of NanoStilbene caused reduction in
serum levels of inflammatory markers TNF-alpha, IL-6, and
CRP
[1]. Additionally, NK
cytotoxicity was augmented, suggesting
that
NanoStilbene may be a useful adjuvant to immunotherapy of cancer
rescuing T cell and NK cell activities. These same
inflammatory molecules are involved in elevated levels of
PSA.
Glucoraphanin, found
primarily in broccoli, is another potent antioxidant like
pterostilbene. The main purpose of
antioxidants is to protect the cells in our body from damage caused
by oxidative stress, namely free radicals, which are unstable
compounds missing an electron. This free
radical
damage is also closely linked with inflammation because the body
recognizes oxidative damage as a threat.
We know what the
result is, a damaging
cycle of
oxidation: damage – immune cells – more damage. Increasing
antioxidant potential in the body provides a solution by helping to
prevent a lot of the oxidative damage in the first
place.
Glucoraphanin, as we
have produced it, is a precursor to our end product which is
another compound called sulforaphane. Glucoraphanin belongs
to a category of compounds called glucosinolates which are
naturally found in cruciferous vegetables. Glucosinolates are
enzymatically converted into isothiocyanates, which are active in
the body. This enzymatic conversion is performed by myrosinase,
which is also found naturally in cruciferous vegetables.
Myrosinase-like activity also occurs in our intestinal microflora
so if glucoraphanin is consumed by itself, our gut microflora will
convert a portion of it to sulforaphane, a compound
within the isothiocyanate group of organosulfur
compounds.
"This is an extremely
exciting development in our research with
our end target compound being sulforaphane. Sulforaphane has been
shown to significantly reduce PSA after 20 weeks of consuming
broccoli sprout extract (BSE).
There is
little misunderstanding that inflammation causes gut dysbiosis
and since we are depending upon the microflora to hydrolyze the
glucoraphanin into sulforaphane it seems perfectly reasonable to
want the gut in the best shape it can be in. We already know
pterostilbene supplementation causes beneficial changes in
microbiota composition, improved metabolic function, strengthened
insulin sensitivity and induced anti-obesity effects
and so we
have blended the two into a single formulation providing a
clinically relevant amount of both actives. Our Mission is to
either up-regulate or down-regulate the immune system and NanoPSA
is another tool in the box to achieve our
mission" said Timothy Dixon,
President and CEO of Therapeutic Solutions International.
"We hope
to have this product available,
which
will come in capsule form, on the shelf,
very
quickly."
[1] https://mynanostilbene.com/?page_id=137
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Jul 2023 to Jul 2024